Qilu Pharma Inks $1.4B Deal to Commercialize ZSP1225, a Novel GLP-1/GIP Dual Agonist for Obesity and Diabetes

Jan 16, 2026 17:35 CST Updated 17:35

Zhongsheng Pharmaceutical

Pharmaceutical R&D and Manufacturer

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

On January 16, Zhongsheng Pharmaceutical announced that its holding subsidiaryRaynovent Signs Licensing Agreement with Qilu Pharmaceutical

Raynovent Authorized Qilu Pharmaceutical in the China region (including mainland China, Hong Kong, Macao, and Taiwan, collectively referred to as the "licensed region") forRAY1225 InjectionProduction and commercial sales of the solution are underway.

Raynovent reserves all rights, ownership, and interests in the licensed intellectual property. After the licensed product receives marketing authorization approval from the pharmaceutical regulatory authority, Raynovent will be the Marketing Authorization Holder (MAH).

At the same time, Raynovent still retains all rights, ownership, and interests of RAY1225 injection outside of China, including but not limited to clinical development, manufacturing, new drug registration, sales, and marketing.

Under the terms of the licensing agreement, Raynovent will receive an upfront payment and milestone payments totaling RMB 1 billion, including an upfront payment of RMB 200 million, development and sales milestone payments up to RMB 800 million in total. After the subsequent product launch, Raynovent is entitled to receive double-digit royalties based on the net sales of the licensed product.

RAY1225 Injection is an innovative peptide drug with a novel structure independently developed by raynovent, featuring dual agonist activity on GLP-1 and GIP receptors. Thanks to its excellent pharmacokinetic properties, it has the potential to be an ultra-long-acting drug administered once every two weeks.

Currently, the Phase III clinical trial (REBUILDING-2 study) for the safety and efficacy of RAY1225 injection in treating obese/overweight patients in China, the Phase III clinical trial (SHINING-3) for the safety and efficacy of RAY1225 injection in combination with oral hypoglycemic drugs for type 2 diabetes patients compared with semaglutide injection, and the placebo-controlled Phase III clinical trial (SHINING-2) for the safety and efficacy of RAY1225 injection as monotherapy for type 2 diabetes patients have all successfully completed participant enrollment.

↓⭐Follow Yaotong Society, gain insights into industry trends ↓
Submission/Corporate Cooperation/Content Communication:
Editor-in-Chief of PharmaCircle—Huaji Meiren (Ww_150525)
*Please indicate remarks and purpose when adding.